No Data
Alvotech, Teva Pharmaceutical's Bionsimlar Eye Disorder Potential Treatment Accepted for FDA Review
SNY and REGN's Dupixent SBLA for Skin Disease Gets FDA's Priority Tag
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in Bullous Pemphigoid
Express News | Regeneron Pharmaceuticals Inc - FDA Decision on This on Dupixent Expected by June 20, 2025
Express News | Dupixent® (Dupilumab) Sbla Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
I also think this is a great biopharmaceutical research and development company, I don't understand why it has been falling all the time.